Healthcare Briefs: Forte Biosciences Acquired In $2.2 Billion Deal By Amsterdam-based Agenx

Dallas-based Forte Biosciences has been acquired by Amsterdam-based Agenx, a global immunology company, for $2.2 billion. The move adds Forte’s lead investigational therapy FB102 to Agenx’s immunology pipeline. FB102 is a first-in-class anti-CD122 antibody being developed to treat autoimmune diseases, including vitiligo and celiac disease, with additional potential applications in other immune-mediated conditions. The acquisition is … Continued The post Healthcare Briefs: Forte Biosciences Acquired In $2.2 Billion Deal By Amsterdam-based Agenx appeared first on D Magazine.
This article was originally published by D Magazine. Read the full story at the source below.
From Our Partners
Best BBQ in Dallas Guide
Discover the top smokehouses in DFW, from Lockhart to Slowbone
DFW Event Tickets
Exclusive deals on concerts, sports & arts across North Texas
Local Hotel Deals
Save up to 30% on stays in Downtown Dallas & Fort Worth
DFW Brewery Pass
Visit 20+ craft breweries across Dallas and Fort Worth
Sponsored links — we may earn a commission at no cost to you